LM-306 / Sino Biopharm, LaNova Medicines Limited - LARVOL DELTA

LM306 - Bridging the Gap: Adding Cortical Potentials to our Pediatric Care (AAA 2026) - "• Upon completion, participants will be able to describe a basic set up for administering cortical testing for pediatric patients. • Upon completion, participants will be able to identify and address common challenges in using CAEPs in clinical settings by utilizing practical insights, clinical tips and collaboration with other pediatric clinicians."

Clinical • Developmental Disorders • Infectious Disease • Otorhinolaryngology • Pediatrics

Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-306 targeting IL-13Rα2 in immuno-oncology (AACR 2023) - "The highest non-severely toxic dose of LM-306 was determined to be 9 mg/kg in the DRF study and MTD was determined to be 18mg/kg in MTD study for male monkey. In summary, LM-306 showed high binding affinity to human IL13Rα2 expressing cells with potent cytotoxicity in vitro and significant in vivo inhibition of tumor growth, suggesting its therapeutic benefit in immuno-oncology.Summary of parameters of LM-106 and LM-306 binding affinity, internalization, ADCC and cytotoxicityAssayAntibody EC50 (nM)HEK293/H_IL-13Rα2U251A375SKMEL5Binding affinityLM-1060.990.210.570.1LM-3061.470.330.80.12InternalizationLM-1062.22-0.43-ADCCLM-1060.16-0.03-LM-3060.31-0.03-Cytotoxicity (IC50)LM-3060.030.050.010.005"

Immuno-oncology • Preclinical • Brain Cancer • CNS Tumor • Glioma • Melanoma • Oncology • Solid Tumor • IL13 • IL13RA2